Patient characteristics and clinical presentation of 37 pediatric patients with pituitary adenomas and cysts
| . | Total casesa,b (n = 37) . | Prolactinomaa (n = 10) . | Nonfunctioning adenomaa (n = 14) . | Cysta (Rathke's cleft or pars intermedia) (n = 8) . |
|---|---|---|---|---|
| Demographics | ||||
| Age, y | 16.1 (14.3-17.5) | 16.6 (14.9-17.4) | 16.1 (14.5-17.1) | 15.2 (12.7-17.3) |
| Female sex | 30 (81%) | 9 (90%) | 12 (86%) | 6 (75%) |
| Male sex | 7 (19%) | 1 (10%) | 2 (14%) | 2 (25%) |
| Female:Male ratio | 4.3:1 | 9.0:1 | 6.0:1 | 3.0:1 |
| Race | ||||
| African | 1 (3%) | |||
| Asian or Pacific Islander | 3 (8%) | 2 (14%) | 1 (13%) | |
| Black or African American | 2 (5%) | 1 (10%) | 1 (7%) | |
| White | 29 (78%) | 9 (90%) | 10 (71%) | 6 (75%) |
| Other or Unknown | 3 (8%) | 1 (10%) | 1 (7%) | 1 (13%) |
| More than one race reported | 1 (3%) | 1 (10%) | ||
| Ethnicity | ||||
| Hispanic or Latino | 2 (5%) | 1 (7%) | ||
| Not Hispanic or Latino | 27 (73%) | 6 (60%) | 10 (71%) | 7 (88%) |
| Unknown | 8 (22%) | 4 (40%) | 3 (21%) | 1 (13%) |
| Imaging indication | ||||
| Nonendocrine concern | 8 (22%) | 1 (10%) | 2 (14%) | 3 (38%) |
| Endocrine concern | 29 (78%) | 9 (90%) | 12 (86%) | 5 (63%) |
| Presenting symptomsc | ||||
| Menstrual abnormalities | 12 (32%) | 7 (70%) | 3 (21%) | 2 (25%) |
| Galactorrhea | 5 (14%) | 2 (20%) | 2 (14%) | 1 (13%) |
| Height, weight, or puberty abnormality | 10 (27%) | 5 (36%) | 3 (38%) | |
| Hormonal lab abnormality | 10 (27%) | 1 (10%) | 7 (50%) | |
| Headache | 11 (30%) | 3 (30%) | 5 (36%) | 2 (25%) |
| Fatigue | 3 (8%) | 3 (21%) | ||
| Nausea | 1 (3%) | 1 (10%) | ||
| Vision change | 1 (3%) | 1 (10%) | 1 (12%) | |
| Otherd | 8 (22%) | 5 (36%) | 2 (25%) | |
| Pubertal status | ||||
| Tanner II or greater | 30 (81%) | 10 (100%) | 13 (93%) | 5 (63%) |
| Pre-pubertal | 2 (5%) | 2 (25%) | ||
| Unknown | 5 (14%) | 1 (7%) | 1 (12%) |
| . | Total casesa,b (n = 37) . | Prolactinomaa (n = 10) . | Nonfunctioning adenomaa (n = 14) . | Cysta (Rathke's cleft or pars intermedia) (n = 8) . |
|---|---|---|---|---|
| Demographics | ||||
| Age, y | 16.1 (14.3-17.5) | 16.6 (14.9-17.4) | 16.1 (14.5-17.1) | 15.2 (12.7-17.3) |
| Female sex | 30 (81%) | 9 (90%) | 12 (86%) | 6 (75%) |
| Male sex | 7 (19%) | 1 (10%) | 2 (14%) | 2 (25%) |
| Female:Male ratio | 4.3:1 | 9.0:1 | 6.0:1 | 3.0:1 |
| Race | ||||
| African | 1 (3%) | |||
| Asian or Pacific Islander | 3 (8%) | 2 (14%) | 1 (13%) | |
| Black or African American | 2 (5%) | 1 (10%) | 1 (7%) | |
| White | 29 (78%) | 9 (90%) | 10 (71%) | 6 (75%) |
| Other or Unknown | 3 (8%) | 1 (10%) | 1 (7%) | 1 (13%) |
| More than one race reported | 1 (3%) | 1 (10%) | ||
| Ethnicity | ||||
| Hispanic or Latino | 2 (5%) | 1 (7%) | ||
| Not Hispanic or Latino | 27 (73%) | 6 (60%) | 10 (71%) | 7 (88%) |
| Unknown | 8 (22%) | 4 (40%) | 3 (21%) | 1 (13%) |
| Imaging indication | ||||
| Nonendocrine concern | 8 (22%) | 1 (10%) | 2 (14%) | 3 (38%) |
| Endocrine concern | 29 (78%) | 9 (90%) | 12 (86%) | 5 (63%) |
| Presenting symptomsc | ||||
| Menstrual abnormalities | 12 (32%) | 7 (70%) | 3 (21%) | 2 (25%) |
| Galactorrhea | 5 (14%) | 2 (20%) | 2 (14%) | 1 (13%) |
| Height, weight, or puberty abnormality | 10 (27%) | 5 (36%) | 3 (38%) | |
| Hormonal lab abnormality | 10 (27%) | 1 (10%) | 7 (50%) | |
| Headache | 11 (30%) | 3 (30%) | 5 (36%) | 2 (25%) |
| Fatigue | 3 (8%) | 3 (21%) | ||
| Nausea | 1 (3%) | 1 (10%) | ||
| Vision change | 1 (3%) | 1 (10%) | 1 (12%) | |
| Otherd | 8 (22%) | 5 (36%) | 2 (25%) | |
| Pubertal status | ||||
| Tanner II or greater | 30 (81%) | 10 (100%) | 13 (93%) | 5 (63%) |
| Pre-pubertal | 2 (5%) | 2 (25%) | ||
| Unknown | 5 (14%) | 1 (7%) | 1 (12%) |
aData presented as n (percentage) or median (interquartile range).
bData include all cases, including 1 thyroid stimulating (TSH)-secreting adenoma, 1 growth hormone (GH)-secreting adenoma, and 3 indeterminate lesions.
cSum of category may be >100% as some patients are in more than 1 category.
dOther symptoms included palpitations, hirsutism, mood change, excessive sweating, orthostatic intolerance, behavioral change, anosmia, or no symptoms.
Patient characteristics and clinical presentation of 37 pediatric patients with pituitary adenomas and cysts
| . | Total casesa,b (n = 37) . | Prolactinomaa (n = 10) . | Nonfunctioning adenomaa (n = 14) . | Cysta (Rathke's cleft or pars intermedia) (n = 8) . |
|---|---|---|---|---|
| Demographics | ||||
| Age, y | 16.1 (14.3-17.5) | 16.6 (14.9-17.4) | 16.1 (14.5-17.1) | 15.2 (12.7-17.3) |
| Female sex | 30 (81%) | 9 (90%) | 12 (86%) | 6 (75%) |
| Male sex | 7 (19%) | 1 (10%) | 2 (14%) | 2 (25%) |
| Female:Male ratio | 4.3:1 | 9.0:1 | 6.0:1 | 3.0:1 |
| Race | ||||
| African | 1 (3%) | |||
| Asian or Pacific Islander | 3 (8%) | 2 (14%) | 1 (13%) | |
| Black or African American | 2 (5%) | 1 (10%) | 1 (7%) | |
| White | 29 (78%) | 9 (90%) | 10 (71%) | 6 (75%) |
| Other or Unknown | 3 (8%) | 1 (10%) | 1 (7%) | 1 (13%) |
| More than one race reported | 1 (3%) | 1 (10%) | ||
| Ethnicity | ||||
| Hispanic or Latino | 2 (5%) | 1 (7%) | ||
| Not Hispanic or Latino | 27 (73%) | 6 (60%) | 10 (71%) | 7 (88%) |
| Unknown | 8 (22%) | 4 (40%) | 3 (21%) | 1 (13%) |
| Imaging indication | ||||
| Nonendocrine concern | 8 (22%) | 1 (10%) | 2 (14%) | 3 (38%) |
| Endocrine concern | 29 (78%) | 9 (90%) | 12 (86%) | 5 (63%) |
| Presenting symptomsc | ||||
| Menstrual abnormalities | 12 (32%) | 7 (70%) | 3 (21%) | 2 (25%) |
| Galactorrhea | 5 (14%) | 2 (20%) | 2 (14%) | 1 (13%) |
| Height, weight, or puberty abnormality | 10 (27%) | 5 (36%) | 3 (38%) | |
| Hormonal lab abnormality | 10 (27%) | 1 (10%) | 7 (50%) | |
| Headache | 11 (30%) | 3 (30%) | 5 (36%) | 2 (25%) |
| Fatigue | 3 (8%) | 3 (21%) | ||
| Nausea | 1 (3%) | 1 (10%) | ||
| Vision change | 1 (3%) | 1 (10%) | 1 (12%) | |
| Otherd | 8 (22%) | 5 (36%) | 2 (25%) | |
| Pubertal status | ||||
| Tanner II or greater | 30 (81%) | 10 (100%) | 13 (93%) | 5 (63%) |
| Pre-pubertal | 2 (5%) | 2 (25%) | ||
| Unknown | 5 (14%) | 1 (7%) | 1 (12%) |
| . | Total casesa,b (n = 37) . | Prolactinomaa (n = 10) . | Nonfunctioning adenomaa (n = 14) . | Cysta (Rathke's cleft or pars intermedia) (n = 8) . |
|---|---|---|---|---|
| Demographics | ||||
| Age, y | 16.1 (14.3-17.5) | 16.6 (14.9-17.4) | 16.1 (14.5-17.1) | 15.2 (12.7-17.3) |
| Female sex | 30 (81%) | 9 (90%) | 12 (86%) | 6 (75%) |
| Male sex | 7 (19%) | 1 (10%) | 2 (14%) | 2 (25%) |
| Female:Male ratio | 4.3:1 | 9.0:1 | 6.0:1 | 3.0:1 |
| Race | ||||
| African | 1 (3%) | |||
| Asian or Pacific Islander | 3 (8%) | 2 (14%) | 1 (13%) | |
| Black or African American | 2 (5%) | 1 (10%) | 1 (7%) | |
| White | 29 (78%) | 9 (90%) | 10 (71%) | 6 (75%) |
| Other or Unknown | 3 (8%) | 1 (10%) | 1 (7%) | 1 (13%) |
| More than one race reported | 1 (3%) | 1 (10%) | ||
| Ethnicity | ||||
| Hispanic or Latino | 2 (5%) | 1 (7%) | ||
| Not Hispanic or Latino | 27 (73%) | 6 (60%) | 10 (71%) | 7 (88%) |
| Unknown | 8 (22%) | 4 (40%) | 3 (21%) | 1 (13%) |
| Imaging indication | ||||
| Nonendocrine concern | 8 (22%) | 1 (10%) | 2 (14%) | 3 (38%) |
| Endocrine concern | 29 (78%) | 9 (90%) | 12 (86%) | 5 (63%) |
| Presenting symptomsc | ||||
| Menstrual abnormalities | 12 (32%) | 7 (70%) | 3 (21%) | 2 (25%) |
| Galactorrhea | 5 (14%) | 2 (20%) | 2 (14%) | 1 (13%) |
| Height, weight, or puberty abnormality | 10 (27%) | 5 (36%) | 3 (38%) | |
| Hormonal lab abnormality | 10 (27%) | 1 (10%) | 7 (50%) | |
| Headache | 11 (30%) | 3 (30%) | 5 (36%) | 2 (25%) |
| Fatigue | 3 (8%) | 3 (21%) | ||
| Nausea | 1 (3%) | 1 (10%) | ||
| Vision change | 1 (3%) | 1 (10%) | 1 (12%) | |
| Otherd | 8 (22%) | 5 (36%) | 2 (25%) | |
| Pubertal status | ||||
| Tanner II or greater | 30 (81%) | 10 (100%) | 13 (93%) | 5 (63%) |
| Pre-pubertal | 2 (5%) | 2 (25%) | ||
| Unknown | 5 (14%) | 1 (7%) | 1 (12%) |
aData presented as n (percentage) or median (interquartile range).
bData include all cases, including 1 thyroid stimulating (TSH)-secreting adenoma, 1 growth hormone (GH)-secreting adenoma, and 3 indeterminate lesions.
cSum of category may be >100% as some patients are in more than 1 category.
dOther symptoms included palpitations, hirsutism, mood change, excessive sweating, orthostatic intolerance, behavioral change, anosmia, or no symptoms.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
